Karyopharm Therapeutics, Inc. (KPTI)
8.06
+0.08
(+1.00%)
USD |
NASDAQ |
May 21, 16:00
8.06
0.00 (0.00%)
After-Hours: 19:59
Karyopharm Therapeutics Total Liabilities (Quarterly) : 397.06M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 32.85B |
| Catalyst Pharmaceuticals, Inc. | 134.91M |
| Oncolytics Biotech, Inc. | 13.29M |
| Altimmune, Inc. | 51.64M |
| Cellectar Biosciences, Inc. | 6.403M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 131.42M |
| Shareholders Equity (Quarterly) | -265.65M |
| Debt to Equity Ratio | -0.8691 |
| Current Ratio | 1.077 |
| Net Debt Paydown Yield | -5.79% |